EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Trends in fluoroquinolone prescribing in UK primary and secondary care between 2019 and 2023

Fergus Hamilton, Elizabeth Darley, Karon Arnold, Alasdair MacGowan

Journal of Antimicrobial Chemotherapy · 03.02.2025 · 80 (2) · 518-527

DOI: 10.1093/jac/dkae440 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 21.12.2024. Verfasst von Fergus Hamilton und 3 weiteren Autor:innen. Beteiligte Einrichtung: MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK. Hauptthemen laut MEDLINE: Drug Prescriptions, Fluoroquinolones, Drug and Narcotic Control. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Fluoroquinolones are important antibiotics but have associations with a number of adverse outcomes. A recent (January 2024) decision by the UK drug regulator, the Medicines and Health Regulatory Authority (MHRA), restricted systemic use of these antibiotics to when ‘absolutely necessary’. One stated reason for the ban was the failure of previous guidance (2019, 2023) to reduce prescribing, with the MHRA stating there had been ‘no change in prescribing’ of fluoroquinolones in relation to guidance.

Methods

We evaluated the trend in prescribing of fluoroquinolones and comparator antibiotics using national data for all primary care practices in England from 2019 to 2023. We calculated the percent change in prescribing of fluoroquinolones using linear regression, comparing with other antibacterials. We also performed analysis on secondary care prescribing and included hospital inpatient stay data.

Results

In primary care, there was a negative trend in fluoroquinolone item dispensing, with a 4.2% reduction in items dispensed per year (95% CI −5.2% to −3.3%; P = 6 × 10−13). This occurred despite no change in overall antibacterial prescription and no decrease in comparator antibiotics. Secondary care data showed stable prescription of fluoroquinolones, but comparator antibiotics increased, leading to relatively fewer prescriptions compared with other agents.

Conclusions

There was a reduction in fluoroquinolone prescribing in England in absolute and relative terms between 2019 and 2023 in primary care, and absolute terms in secondary care. These findings do not support the MHRA’s claim that there has been no change in prescribing in response to warnings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug PrescriptionsFluoroquinolonesDrug and Narcotic ControlPrimary Health CareSecondary Health CareUnited KingdomHumans

Substanzen

Fluoroquinolones

Autor:innen und Institutionen

  • MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
  • Infection Science, North Bristol NHS Trust, Bristol, UK.
  • Bristol, South Gloucestershire, and North Somerset Integrated Care Board, Bristol, UK.

Förderung

  • Wellcome Trust

Zitieren

APA

Hamilton, F., Darley, E., Arnold, K., & MacGowan, A. (2025). Trends in fluoroquinolone prescribing in UK primary and secondary care between 2019 and 2023. Journal of Antimicrobial Chemotherapy, 80(2), 518-527. https://doi.org/10.1093/jac/dkae440

Vancouver

Hamilton F, Darley E, Arnold K, MacGowan A. Trends in fluoroquinolone prescribing in UK primary and secondary care between 2019 and 2023. Journal of Antimicrobial Chemotherapy. 2025;80(2):518-527. doi:10.1093/jac/dkae440

BibTeX
@article{Hamilton2025,
  author = {Hamilton, Fergus and Darley, Elizabeth and Arnold, Karon and MacGowan, Alasdair},
  title = {Trends in fluoroquinolone prescribing in UK primary and secondary care between 2019 and 2023},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  volume = {80},
  number = {2},
  pages = {518--527},
  doi = {10.1093/jac/dkae440}
}
Kostenlos starten →